Moss Adams Wealth Advisors LLC Sells 737 Shares of Danaher Co. (NYSE:DHR)

Moss Adams Wealth Advisors LLC reduced its position in Danaher Co. (NYSE:DHR) by 18.3% in the 1st quarter, Holdings Channel reports. The firm owned 3,283 shares of the conglomerate’s stock after selling 737 shares during the quarter. Moss Adams Wealth Advisors LLC’s holdings in Danaher were worth $674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. LaFleur & Godfrey LLC lifted its holdings in shares of Danaher by 1.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,855 shares of the conglomerate’s stock valued at $6,853,000 after acquiring an additional 440 shares during the period. Union Bancaire Privee UBP SA bought a new position in shares of Danaher during the fourth quarter valued at $74,551,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Finally, Cidel Asset Management Inc. lifted its holdings in shares of Danaher by 5.8% during the fourth quarter. Cidel Asset Management Inc. now owns 1,810 shares of the conglomerate’s stock valued at $415,000 after acquiring an additional 100 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR stock opened at $196.13 on Monday. The firm has a market cap of $140.36 billion, a price-to-earnings ratio of 37.15, a PEG ratio of 2.66 and a beta of 0.77. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The stock has a 50-day moving average price of $191.34 and a 200 day moving average price of $212.03. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. Research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher’s payout ratio is currently 24.85%.

Insider Transactions at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company’s stock, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on DHR shares. Barclays raised their target price on Danaher from $205.00 to $215.00 and gave the company an “overweight” rating in a research note on Tuesday, April 22nd. Guggenheim restated a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Monday. The Goldman Sachs Group lowered their target price on Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a research note on Wednesday, April 23rd. Finally, Jefferies Financial Group lowered their target price on Danaher from $260.00 to $230.00 and set a “buy” rating for the company in a research note on Tuesday, April 22nd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $263.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.